AEON Biopharma Files 8-K for Financials

TL;DR

AEON Biopharma filed an 8-K for financial statements and exhibits on April 15, 2024.

AI Summary

AEON Biopharma, Inc. filed an 8-K on April 15, 2024, reporting on financial statements and exhibits. The company, formerly known as Priveterra Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations industry. This filing does not appear to contain specific financial figures or material events beyond the standard reporting of financial statements and exhibits.

Why It Matters

This filing indicates AEON Biopharma is meeting its reporting obligations, providing transparency to investors regarding its financial statements and exhibits.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

• AEON Biopharma, Inc. (company) — Registrant
• Priveterra Acquisition Corp. (company) — Former company name
• April 15, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Irvine, CA (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share AEON NYSE Ameri
• $7.6994 — f the Warrant Agreement, to be equal to $7.6994 and (b) based on the Redemption Fair Ma
• $0.10 — cept to receive the redemption price of $0.10 per Public Warrant. A copy of the Supp

Filing Documents

• aeon-20240415x8k.htm (8-K) — 45KB
• aeon-20240415xex99d1.htm (EX-99.1) — 8KB
• 0001837607-24-000026.txt ( ) — 241KB
• aeon-20240415.xsd (EX-101.SCH) — 4KB
• aeon-20240415_def.xml (EX-101.DEF) — 14KB
• aeon-20240415_lab.xml (EX-101.LAB) — 16KB
• aeon-20240415_pre.xml (EX-101.PRE) — 14KB
• aeon-20240415x8k_htm.xml (XML) — 7KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. As previously disclosed, on March 29, 2024, AEON Biopharma, Inc. (the "Company") announced the redemption on April 29, 2024 (the "Redemption Date") of all of its outstanding public warrants (the "Public Warrants") to purchase shares of the Company's Class A common stock, par value $0.0001 per share ("Common Stock"), that were issued under the Warrant Agreement, dated February 8, 2021, by and between the Company and Continental Stock Transfer & Trust Company ("CST"), as warrant agent (the "Warrant Agreement"), as part of the units sold in the Company's initial public offering. In its capacity as warrant agent, CST has delivered a notice (the "Supplemental Notice of Redemption") to each of the registered holders of the outstanding Public Warrants on behalf of the Company informing holders that (a) the "Redemption Fair Market Value" (as defined in the Warrant Agreement) has been calculated, in accordance with Section 6.2 of the Warrant Agreement, to be equal to $7.6994 and (b) based on the Redemption Fair Market Value and the redemption date of April 29, 2024, the number of shares of Common Stock issuable in connection with any exercise of the Public Warrants on a "cashless basis" will be equal to approximately 0.2456 shares of Common Stock per Public Warrant. As previously disclosed, and in accordance with the Warrant Agreement, any Public Warrants that remain unexercised at 5:00 p.m. New York City time on the Redemption Date will be void and no longer exercisable and their holders will have no rights with respect to those Public Warrants, except to receive the redemption price of $0.10 per Public Warrant. A copy of the Supplemental Notice of Redemption delivered by the Company is filed as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this current report on Form 8-K, including Exhibit 99.1, is "furnished," not "filed," for the purposes of Section 18 of the Securities Exchange Act of 1934, as a

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Supplemental Notice of Redemption, dated April 15, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: April 15, 2024 By: /s/ Marc Forth Marc Forth Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR